She W, Lv L, Du X, Li H, Dai Y, Lu L, Ma X, Chen F
Department of Otolaryngology-Head and Neck Surgery,Nanjing Drum Tower Hospital of Nanjing University Medical School,Jiangsu,China.
Department of Otolaryngology-Head and Neck Surgery,Huai'an First People's Hospital,Nanjing Medical University,Jiangsu,China.
J Laryngol Otol. 2015 Mar;129(3):232-7. doi: 10.1017/S0022215115000171. Epub 2015 Feb 6.
This study aimed to investigate the long-term efficacy of intratympanic methylprednisolone perfusion treatment for intractable Ménière's disease.
A retrospective analysis of 17 intractable Ménière's disease patients treated with intratympanic methylprednisolone perfusion was performed. Treatment efficacy was evaluated according to the American Academy of Otolaryngology-Head and Neck Surgery criteria. Short and long-term control or improvement rates were calculated after 6 and 24 months, respectively.
Sixteen patients were followed for more than two years. Short- and long-term vertigo control rates were 94 per cent and 81 per cent, respectively; short- and long-term functional activity improvements were 94 per cent and 88 per cent, respectively. The pure tone average was 53 ± 14 dB before treatment, and 50 ± 16 dB at 6 months and 52 ± 20 dB at 24 months after intratympanic methylprednisolone perfusion. Tinnitus was controlled or improved in five patients over the two-year follow-up period.
Intratympanic methylprednisolone perfusion can effectively control vertigo and improve functional activity in intractable Ménière's disease patients with good hearing preservation. It may therefore be a viable alternative treatment for intractable Ménière's disease.
